AACR 2023 Poster 4570

Expanding the 3D Ex Vivo Patient Tissue Platform Toolbox for Immuno-Oncology Drug Testing

Nataliia Beztsinna, Sander Basten, Ezgi Kaya Aksoy, Niels Meesters, Stefanos Timiliotis, Donny van der Meer, Kuan Yan, Emma Spanjaard, Willemijn Vader and Leo Price

Crown Bioscience, Inc., Leiden, The Netherlands VitroScan B.V. Leiden, The Netherlands

This poster provides information about a 3D Ex vivo Patient Tissue Platform based on a short-term 3D ex vivo tumor culture system followed by high content imaging (HCI)-based analysis. The platform has previously been validated for standard of care and immunological drug testing, including immune checkpoint inhibitors (ICI), in ovarian and non-small cell lung cancer (NSCLC) samples. The expansion of the Ex vivo Patient Tissue platform to other cancer indications is presented, including resections from bladder-, prostate-, breast cancer, melanoma, glioblastoma, and cholangiocellular carcinoma.

Download this Poster to Discover:

• The success rate of the assay on newly tested indications and established indications. 
  
  
• Factors contributing to high success rates.
  
  
• Application of the platform as an innovative and translational tool for complex immuno-oncology drug testing in multiple cancer indications.

Download the Poster Now!